Home/Science/Publications

Publications

Peer-reviewed manuscripts and scientific posters from the Fedora team on our programs.

Contact us for copies of the full posters.

Poster  |  FPI-2119  |  ESCMID 2026  |  Munich

P2568: FPI-2119 Bactericidal activity and resistance selection in Pseudomonas aeruginosa

Poster  |  FPI-2119  |  ESCMID 2026  |  Munich

P2580: Stability of a new antibiotic derivative of the lactivicin class, FPI-2119, against isogenic Escherichia coli strains producing a broad array of clinically important and potent β-lactamases

Poster  |  FPI-2119  |  ESCMID 2026  |  Munich

P2581: Activity of a new antibiotic derivative of the lactivicin class, FPI-2119, tested against contemporary collections of intestinal and respiratory pathogens including resistant subsets

Poster  |  FPI-2119  |  ESCMID 2026  |  Munich

P2583: In vitro activity of a new antibiotic derivative of the lactivicin class, FPI-2119, tested against a panel of Neisseria gonorrhoeae showing various resistance phenotypes, including multidrug resistance

Poster  |  FPI-2119  |  ESCMID 2026  |  Munich

P2599: Evaluation of the in vitro and in vivo safety profile of FPI-2119

Poster  |  FPI-2119  |  ESCMID 2026  |  Munich

P2601: Penicillin-binding protein binding profiles to a new, non-β-lactam PBP-binding antibiotic (FPI-2119) in Pseudomonas aeruginosa

Poster  |  FPI-2119  |  ESCMID 2026  |  Munich

P2643: Antibacterial efficacy of FPI-2119 against Escherichia coli in a murine urinary tract infection model

Poster  |  FPI-2119  |  ESCMID 2026  |  Munich

P2801: Population pharmacokinetics of FPI-2119, a new lactivicin-derived antibiotic, in infected and uninfected mice using a staggered serial-sampling study design

Poster  |  FPI-2119  |  IMARI 2026  |  Las Vegas

P245: FPI-2119 Bactericidal activity and resistance selection in Enterobacterales

Poster  |  FPI-2119  |  IMARI 2026  |  Las Vegas

P252: In vivo activity of FPI-2119 against Klebsiella pneumoniae in murine models of bacterial septicemia and lung infection

Poster  |  FPI-2119  |  IMARI 2026  |  Las Vegas

P254: In vitro activity of FPI-2119 against multidrug-resistant, carbapenem-producing Gram-negative pathogens: a first-in-class broad-spectrum antibacterial agent

Poster  |  FPI-2119  |  IMARI 2026  |  Las Vegas

P255: Penicillin-binding protein (PBP) binding patterns and morphological changes of Escherichia coli and Klebsiella pneumoniae in response to a new, non-β-lactam PBP-binder (FPI-2119)

Poster  |  Nacubactam & DBO BLIs  |  ACC 2021  |  Virtual

In vitro activity of Meropenem/Nacubactam against biodefense and emerging infectious disease pathogens

Poster  |  Nacubactam & DBO BLIs  |  ACC 2021  |  Virtual

In vitro antimicrobial activity of Nacubactam and β-Lactam-Nacubactam combinations against Enterobacteriaceae clinical isolates containing OXA-48-like genes

Poster  |  Nacubactam & DBO BLIs  |  ECCMID 2018  |  Madrid

P1034: Nacubactam (NAC) antibacterial activity alone and in combination with β-lactam antibiotics against contemporary clinical Enterobacteriaceae

Poster  |  Nacubactam & DBO BLIs  |  ECCMID 2018  |  Madrid

P1035: Pharmacokinetic and pharmacodynamics of Nacubactam in combination with Meropenem in a one-compartment PK-PD in vitro infection model

Poster  |  Nacubactam & DBO BLIs  |  ECCMID 2018  |  Madrid

P1035A: Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling of the efficacy of meropenem/nacubactam against β-lactamase producing Enterobacteriaceae

Poster  |  Nacubactam & DBO BLIs  |  ECCMID 2018  |  Madrid

P1036: Fitness and pathogenicity evaluation of in vitro Meropenem/Nacubactam-derived mutants

Poster  |  Nacubactam & DBO BLIs  |  ECCMID 2018  |  Madrid

P1037: In vitro evaluation of resistance development against Meropenem/Nacubactam combination in clinical Enterobacteriaceae isolates

Poster  |  Nacubactam & DBO BLIs  |  ECCMID 2018  |  Madrid

P1038: Genomic characterization of bacterial colonies resistant to nacubactam alone and in combination with meropenem

Poster  |  Nacubactam & DBO BLIs  |  ECCMID 2018  |  Madrid

P1039: In vitro activity of Nacubactam, a novel dual action diazabicyclooctane, alone and with meropenem, against beta-lactamase-positive Enterobacteriaceae

Poster  |  Nacubactam & DBO BLIs  |  ECCMID 2018  |  Madrid

P1041: In vivo efficacy of the meropenem/nacubactam combination against in vitro-generated resistant mutants

Poster  |  Nacubactam & DBO BLIs  |  ECCMID 2018  |  Madrid

P2209: Population pharmacokinetic analysis of the β-lactamase inhibitor

Poster  |  Nacubactam & DBO BLIs  |  ECCMID 2018  |  Madrid

P2214: Safety, tolerability and pharmacokinetics of nacubactam, a novel β-

Poster  |  Nacubactam & DBO BLIs  |  ICAAC 2013  |  Denver

C1-059: Mechanistic studies of inhibition of CTX-M-15 and KPC-2 β-lactamases by the β-lactamase inhibitor FPI-1465

Poster  |  Nacubactam & DBO BLIs  |  ICAAC 2013  |  Denver

F-1188: Activity of β-lactam agents tested in combination with novel β-lactamase inhibitor compounds against Enterobacteriaceae producing extended-spectrum β-lactamases

Poster  |  Nacubactam & DBO BLIs  |  ICAAC 2013  |  Denver

F-1189: β-Lactam activity tested in combination with β-lactamase inhibitor candidates against Enterobacteriaceae producing Class A, B and D carbapenemases

Poster  |  Nacubactam & DBO BLIs  |  ICAAC 2013  |  Denver

F-1190: Design, synthesis and structure activity relationship of novel substituted amides containing diaza bicyclic heterocyclic compounds as broad-spectrum β-lactamase inhibitors

Poster  |  Nacubactam & DBO BLIs  |  ICAAC 2013  |  Denver

F-1191: Mechanistic studies of FPI-1465, a novel β-lactamase inhibitor

Poster  |  Nacubactam & DBO BLIs  |  ICAAC 2013  |  Denver

F-1192: In vitro checkerboard and time-kill synergy studies of a novel β-lactamase inhibitor (FPI-1465) in combination with ceftazidime (CAZ)

Poster  |  Nacubactam & DBO BLIs  |  ICAAC 2013  |  Denver

F-1193: Structural insights into inhibition of the CTX-M15 serine β-lactamase by FPI-1465

Poster  |  Nacubactam & DBO BLIs  |  ICAAC 2013  |  Denver

F-1194: Efficacy of ceftazidime (CAZ) in combination with FPI-1465 a novel β-lactamase inhibitor in neutropenic murine thigh models caused by KPC-2 producing Klebsiella pneumoniae and VIM-1 & KPC-3 producing Enterobacter cloacae

Poster  |  Nacubactam & DBO BLIs  |  ICAAC 2013  |  Denver

F-1195: Pharmacokinetics of novel β-lactamase inhibitor FPI-1465 in mouse and rat after single intravenous administration

Poster  |  Nacubactam & DBO BLIs  |  ICAAC 2013  |  Denver

F-1196: Inhibition of CYP450s and in vitro and in vivo safety profile of FPI-1465 a novel non-β-lactam β-lactamase inhibitor

Designed by Gravitas Digital in partnership with